PCG
DFTX

Private Capital Group’s Definium Therapeutics DFTX Stock Holding History

Private Capital Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-406
Closed -$7K – 2023
2022
Q1 		$7K Hold
406
– – ﹤0.01% 1400
2021
Q4 		$8K Hold
406
– – ﹤0.01% 1391
2021
Q3 		$15K Buy
+406
New +$17.6K ﹤0.01% 1196

Other funds holding DFTX

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $78.6M AUM 55.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $4.12B AUM 32.66% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Private Capital Group's DFTX Position: Q2 2022 in Review

Private Capital Group sold out of Definium Therapeutics (DFTX) in Q2 2022, closing a stake of 406 shares — an estimated $7K sold.

Private Capital Group first reported a position in DFTX in Q3 2021 and held it in 3 quarters. The position peaked at $15K in Q3 2021. 155 funds tracked by Wall St. Rank hold DFTX as of Q2 2022.

  • Private Capital Group reported no remaining Definium Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Private Capital Group sold 406 Definium Therapeutics shares in Q2 2022, an estimated $7K.
  • Private Capital Group first reported a position in Definium Therapeutics in Q3 2021 and held it in 3 quarters.
  • Private Capital Group's Definium Therapeutics position peaked at $15K in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.